CEOInterviews.AI
Start App
Noubar Afeyan
Founder & CEO, Flagship Pioneering

El CEO de Flagship Pioneering, Noubar Afeyan, habla sobre health tech en Semafor World Economy

📅 May 14, 2026 New York Stock Exchange 11 MIN 5 VIEWS 18 SEGMENTS · 2 SPEAKERS

What Noubar Afeyan said

Written from the verified transcript and checked against it. Every figure links to the moment it was said.

Noubar Afeyan, founder and CEO of Flagship Pioneering, discussed AI's impact on healthcare and science at the Semafor World Economy Summit. He described AI as transforming the scientific method by generating hundreds of hypotheses, designing experiments, and running automated labs, calling it 'Waymo for scientific discovery.' He argued that US innovation depends on migration policy, basic research funding, and competition with China in biotech, warning against cutting research funding. He introduced the concept of 'poly-intelligence,' suggesting machine intelligence can better understand nature's forms of intelligence. He highlighted biology's programmability, citing Moderna's mRNA scale-up from hundreds to a billion doses in a year. He explained Flagship's long-term approach, focusing on 'uncertainty resolution' and converting uncertainty into risk. He mentioned 16 AI-based companies, including Lila Sciences, a 3-year-old, 300-person firm using AI to drive the scientific method.

Key takeaways

  1. Flagship has 16 AI-based companies applied to science, including Lila Sciences, a 3-year-old, 300-person firm using AI to drive the entire scientific method.
  2. Moderna scaled mRNA from hundreds of doses to a billion doses in a year during the pandemic, showing biotech's scalability.
  3. US innovation edge depends on migration policy, basic research funding, and competition with China in biotech, which is feeling effects of China's centrally planned economy.
  4. AI is making biology programmable, moving from artisanal to industrial and scalable, similar to IT's modular, reusable ideas.
  5. Flagship's approach is to convert uncertainty into risk, focusing on long-term opportunities where they can be the only game in town.

Numbers and commitments

FigureWhat it refers toTypeAt
16 AI-based companies across Flagship metric 8:51
3 years old Age of Lila Sciences metric 8:51
300 people Employees at Lila Sciences metric 8:51

Chapters

  1. 0:00AI's impact on healthcare
  2. 1:51US innovation edge
  3. 4:01AI and scientific method
  4. 5:31Programmable biology
  5. 7:40Long-term investing approach
  6. 8:51Uncertainty resolution

Questions asked in this interview

6
  1. 0:18What brings you to the summit?
  2. 0:38How are you finding that artificial intelligence is impacting your sector of healthcare?
  3. 1:47What does America need to do to keep its innovation edge?
  4. 3:53What is the impact that AI is having and can potentially have when it comes to scientific methods?
  5. 5:27What excites you that you see in the pipeline?
  6. 7:33I want to ask you in your role, Noubar, how you invest for the long term in a short-term headline-driven market?
Interviewer 0:06 ↗
We're here at the Semafor World Economy Summit and I'm pleased to be joined by a marquee speaker at this summit. It's Noubar Afeyan, he's Flagship Pioneering founder and CEO. Noubar, welcome.
Noubar Afeyan 0:16 ↗
Good to be here.
Interviewer 0:18 ↗
Yeah, it's great to speak with you. What brings you to the summit?
Noubar Afeyan 0:21 ↗
Well, I'm going to be joining a panel with Gary Cohn from IBM and we're going to talk about how the current moment presents some opportunities and challenges technologies, particularly in my space of healthcare and the changes that are going on and how we can actually compete more effectively.
Interviewer 0:38 ↗
How are you finding that artificial intelligence is impacting your sector of healthcare?
Noubar Afeyan 0:43 ↗
Well, there's a way that it's affecting every sector and it's also affecting healthcare, which is productivity, simplifying work, and making things more efficient. But then there's a unique way in which AI is affecting science, which is really completely different territory. And that is the whole scientific method is increasingly being leveraged by AI and then leveraging of AI in the sense that we're using generative AI to come up with new hypotheses, not one at a time, but hundreds of them at a time. We're using AI to design experimental protocols that otherwise hundreds of scientists would be involved in doing. And then we're actually running experiments increasingly in automated labs and then interpreting the data. That whole wheel of science that's historically been very important as to its output, but very inefficient and slow, is becoming AI-ified, if I can call it that. And it's really a marvel to see because we don't really know kind of where it goes. It's a little like Waymo for scientific discovery, to put it in a kind of a trivial way, but it's really potent and we're just beginning to see the effects of that.
Interviewer 1:47 ↗
What does America need to do to keep its innovation edge?
Noubar Afeyan 1:51 ↗
Well, so many things I think have contributed to our innovation edge. I'd say first and foremost, our migration policy has been a huge part of that in the sense that we've attracted the best and brightest from the world and we've been able to incent them to stay here and to contribute and that's been a very big driver. I think that the policies that we use in terms of funding basic research that leads to some of the major breakthroughs. There's a whole continuum. People don't realize when they see a breakthrough, when some satellite gets shot up in the sky and does wonderful things, that where does that come from? And the answer is a consistent investment in basic research that follows by applied research, follows by entrepreneurial research, all the way to companies that can create these products. There is a real battle going on as to whether that research is worth it and whether we should just get out of the business of funding scientific research by and large and that's really scary in my view. Then there's competitiveness issues, you know, we're competing with China in certain sectors, particularly in biotechnology and we definitely are feeling the effects of that because they have a centrally planned economy that's focusing on some areas of relative advantage for them, particularly new drugs that can be developed very efficiently there and the US biotech industry is feeling that. Now, competition is good in general cuz it makes you even better, but competition based on policies that are very different as to what it takes to take something into the clinic and test it in humans or the ability to aggregate data from lots of places so you can make much better decisions. These are things that are essentially not possible in the US. We're not organized that way. So, we've been advocating that there needs to be attention paid to some of the conditions for us to maintain our competitive edge. So, I think that the challenges bring opportunities. The startup community that's very healthy in the US, we need to make sure we're protecting that advantage. Obviously, large companies are also competing. So, how do we create the dynamics right to make sure that happens? All of that goes into competitive advantage and innovation.
Interviewer 3:53 ↗
What is the impact that AI is having and can potentially have when it comes to scientific methods?

9 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Afeyan, N. (2026, May 14). El CEO de Flagship Pioneering, Noubar Afeyan, habla sobre health tech en Semafor World Economy [Interview transcript]. New York Stock Exchange. CEOInterviews.AI. https://ceointerviews.ai/interview/919519/

MLA

Noubar Afeyan. "El CEO de Flagship Pioneering, Noubar Afeyan, habla sobre health tech en Semafor World Economy." New York Stock Exchange, 14 May. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/919519/.

BibTeX
@misc{afeyan2026_919519,
  author       = {Noubar Afeyan},
  title        = {El CEO de Flagship Pioneering, Noubar Afeyan, habla sobre health tech en Semafor World Economy},
  howpublished = {Interview transcript, New York Stock Exchange. CEOInterviews.AI},
  year         = {2026},
  month        = {may},
  url          = {https://ceointerviews.ai/interview/919519/},
  note         = {Speaker-attributed transcript with timestamps}
}